

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOCON BIOLOGICS INC.,

Petitioner,

v.

JANSSEN BIOTECH, INC.,

Patent Owner.

Case No. IPR2023-01444

Patent No. 10,961,307

**JOINT REQUEST THAT SETTLEMENT AGREEMENT BE TREATED
AS BUSINESS CONFIDENTIAL INFORMATION AND KEPT
SEPARATE UNDER 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)**

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c) and the Board's authorization of February 28, 2024, Patent Owner Janssen Biotech, Inc. ("Patent Owner") and the Petitioner Biocon Biologics Inc. ("Petitioner") jointly request that the true and complete copy of their settlement agreement (Confidential Exhibit 1073), referenced in the concurrently-filed Joint Motion for Termination, be treated as confidential business information. As such, the Parties request that Confidential Exhibit 1073 be kept separate from the files of the involved patent and IPR2023-01444, and only made available to Federal Government agencies upon written request or to any other person upon written request and a showing of good cause.

Respectfully submitted,

Date: March 1, 2024

/s/ Scott Border
Scott Border, Reg. No. 77,744 Counsel
for Petitioner

Date: March 1, 2024

/s/ Michael A. Morin
Michael A. Morin, Reg. No. 40,734
Counsel for Patent Owner

CERTIFICATE OF SERVICE

The undersigned certifies that a copy of the foregoing **Joint Request that Settlement Agreement be Treated as Business Confidential Information and be Kept Separate Under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.72(c)** was served electronically via email on counsel of record on March 1, 2024.

Patent Owner has consented to electronic service by email.

Dated: March 1, 2024

/s/ Scott Border
Scott Border
Winston & Strawn LLP
Counsel for Petitioner